Neurologically, GLP-1 RAs demonstrate neuroprotective effects, reducing neuroinflammation and improving cognitive function in conditions like Alzheimer's and Parkinson's disease, but their association with dizziness, headaches, and psychiatric adverse effects underscores the importance of patient-specific evaluations. This evidence concerns the gene GCG and Parkinson disease.